Zależny od dawki wzrost śmiertelności w przypadku Vesnarinone wśród pacjentów z ciężką niewydolnością serca ad 8

Cohn (przewodniczący badania), S. Goldstein, BH Lorell, BH Greenberg; Komitet Śmiertelności i Zachorowalności – A. Feldman (cochairman), J. Young (cochairman), R. Bourge, P. Carson i B. Jaski; Komitet monitorujący dane i bezpieczeństwo – R. Capone (przewodniczący), J. Wilson, BW Brown, Jr., M. Hess; Niezależny statystyk – D. DeMets; Centra kliniczne i badacze – E. Kasper, Johns Hopkins Hospital, Baltimore; J. Strobeck, Valley Hospital, Ridgewood, NJ; T. LeJemtel, Albert Einstein Hospital, Bronx, NY; E. Powers, University of Virginia, Charlottesville; G. Hendrix, Medical University of South Carolina, Charleston; S. Gottlieb, Johns Hopkins Bayview Medical Center, Baltimore; M. Higginbotham, Duke University Medical Center, Durham, NC; T. DeMarco, University of California, San Francisco; P. Carson, Veterans Affairs Medical Center i Georgetown University Hospital, Washington, DC; M. Gilbert, University of Utah, Salt Lake City; R. Schlant, Emory University School of Medicine, Atlanta; R. Wright, Pacific Heart Institute, Santa Monica, Kalifornia; J. O Brien, Fairfax Hospital, Falls Church, VA .; R. Hershberger, Oregon Health Sciences University, Portland; B. Jaski, San Diego Cardiac Center, San Diego, Kalifornia; GW Dec, Massachusetts General Hospital, Boston; M. Goodman, Cardiovascular Medical Associates, Garden City, NY; R. Lee, Mayo Clinic, Scottsdale, Ariz .; M. Jessup, Medical College of Pennsylvania, Filadelfia; A. Feldman, Presbyterian University Hospital, Pittsburgh; C. Pepine, Veterans Affairs Medical Center, Gainesville, Fla .; AB Miller, University of Florida, Jacksonville; J. Abrams, University of New Mexico, Albuquerque; U. Thadani, University of Oklahoma, Oklahoma City; R. Bourge, University of Alabama, Birmingham; G. Levy, Methodist Hospital, Houston; W. Abraham, University of Colorado, Denver; MA Silver, Loyola University Medical Center, Maywood, Illinois; G. Bhat, University of Cincinnati, Cincinnati; F. McGrew, III, Cardiology Group of Memphis, Memphis, Tenn .; M. Fowler, Stanford University School of Medicine, Stanford, Kalifornia; R. Hobbs, Cleveland Clinic Foundation, Cleveland; CA Vander Ark, University of Wisconsin, Madison; TB Levine, Henry Ford Hospital, Detroit; B. Abramowitz, Christ Hospital and Medical Center, Oak Lawn, Illinois; S. Kubo, University of Minnesota, Minneapolis; S. Brozena, Szpitale Uniwersytetów Allegheny, Filadelfia; R. Rodeheffer, Mayo Clinic, Rochester, Minnesota; CW Yancy, Jr., University of Texas Southwestern Medical Center, Dallas; D. Schulman, Allegheny General Hospital, Pittsburgh; C. Moore, University of Mississippi Medical Center, Jackson; MR Costanzo, Rush-Presbyterian-St. Luke s Medical Center, Chicago; C.-S. Liang, University of Rochester Medical Center, Rochester, NY; GS Uhl, Nevada Research Consultants, Las Vegas; S. Krueger, Lincoln Cardiology Associates, Lincoln, Nebr .; R. Chahine, Jackson Memorial Hospital, Miami; J. Boehmer, Milton S. Hershey Medical Center, Hershey, PA .; S. Khan, Cedars-Sinai Medical Center, Los Angeles; D. Fishbein, University of Washington, Seattle; E. Haeusslein, California Pacific Medical Center, San Francisco; M. Greenspan, Buxmont Cardiology Associates, Sellersville, PA .; M
[więcej w: bromazepam, celiprolol, belimumab ]
[więcej w: citalopram, dygestorium, designerskie wieszaki ]
[patrz też: penire plus opinie, ph metria, picie oleju lnianego ]